Jeffrey Bruner, DO
Allergy & Immunology · Clinton Twp, MINPI 1215955422
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,463 of the $18,450 with a category attached, or 78.4%. 36 manufacturers reported payments, led by AstraZeneca at 36.9% of the total. Reporting peaked in 2019 at $5,172 and has fallen 56.0% since, to $2,277 in 2025.
Across 735 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- GSK$2K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Alk-abello, Inc$811
- plus $5K from 30 others
Across 11 payments — averaging $1763.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$14K
- Merck$6K
What the payments were for
- Consulting fees$3602%
- Speaking & faculty fees$2,65014%
- Travel & lodging$8264%
- Food & beverage$14,46378%
- Education$1511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 158 | $6,805 |
| GSK | 137 | $1,797 |
| Sanofi | 50 | $1,567 |
| Regeneron Healthcare Solutions, Inc. | 59 | $1,276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $1,066 |
| Alk-abello, Inc | 35 | $811 |
| CSL Behring | 34 | $732 |
| Amgen | 43 | $724 |
| Novartis | 31 | $679 |
| Teva Pharmaceuticals USA, Inc. | 25 | $501 |
| Genentech USA, Inc. | 22 | $462 |
| Boehringer Ingelheim | 16 | $318 |
| Pfizer | 18 | $297 |
| Kaleo, Inc. | 12 | $219 |
| Covis Pharma GmbH | 7 | $113 |
| Shire North American Group Inc | 6 | $109 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $104 |
| Biocryst US Sales Co., LLC | 3 | $96 |
| Bio Products Laboratory USA, Inc. | 6 | $96 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Grifols USA, LLC | 3 | $68 |
| AbbVie | 3 | $64 |
| Circassia Inc. | 4 | $53 |
| Phadia US Inc. | 3 | $53 |
| LEO Pharma Inc. | 2 | $46 |
| Optinose US, Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Organon | 2 | $33 |
| Hikma Pharmaceuticals USA | 2 | $29 |
| Mylan Specialty L.p. | 1 | $27 |
| Pharming Healthcare, Inc. | 1 | $27 |
| Hospira, Inc. | 1 | $23 |
| Octapharma USA, Inc. | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Merck | 1 | $18 |
| Dermavant Sciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,450 in reported general payments places this provider in the 85th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 228 | $260,346 |
| Dupixent PenDupilumab | 50 | $181,803 |
| Spiriva RespimatTiotropium Bromide | 117 | $126,672 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $58,708 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $51,885 |
| Arnuity ElliptaFluticasone Furoate | 84 | $34,855 |
| Qvar RedihalerBeclomethasone Dipropionate | 80 | $34,275 |
| DuleraMometasone/Formoterol | 28 | $21,518 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $21,065 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $20,523 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $17,582 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $16,264 |
| Pulmicort FlexhalerBudesonide | 36 | $13,377 |
| AlvescoCiclesonide | 18 | $9,661 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $8,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,797 | $355,833406 claims |
| Boehringer IngelheimSpiriva Respimat | $318 | $126,672117 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $6,805 | $89,667148 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $501 | $34,27580 claims |
| MerckDulera | $18 | $21,51828 claims |
| Covis Pharma GmbHAlvesco | $113 | $9,66118 claims |
| Hikma Pharmaceuticals USAEpinephrine | $29 | $3,29414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Clinton Twp
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
- Jason ParisLivonia$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.